Akums Drugs and Pharmaceuticals Ltd
AKUMSAkums Drugs and Pharmaceuticals Ltd
AKUMSPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
36.27 | 13.98 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
50.09 | 6.40 | 0.53% |
Forecast & Ratings
Detailed Forecast from 1 analyst
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Akums Drugs and Pharmaceuticals is pharmaceutical contract development and manufacturing company.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 2,441.65 | 2,744.13 | 3,694.72 | 3,744.89 | 4,212.21 | 4,121.88 | ||||||
Raw Materials | 1,502.95 | 1,738.37 | 2,432.80 | 2,249.87 | 2,537.90 | 3,732.24 | ||||||
Power & Fuel Cost | 82.59 | 76.55 | 110.22 | 147.41 | 160.80 | |||||||
Employee Cost | 438.75 | 424.55 | 507.76 | 590.13 | 646.86 | |||||||
Selling & Administrative Expenses | 82.57 | 100.99 | 127.52 | 159.99 | 160.81 | |||||||
Operating & Other expenses | 134.35 | 154.83 | 598.29 | 288.14 | 574.86 | |||||||
EBITDA | 200.44 | 248.84 | -81.87 | 309.35 | 130.98 | 389.64 | ||||||
Depreciation/Amortization | 66.68 | 69.84 | 94.68 | 112.81 | 125.64 | 134.43 | ||||||
PBIT | 133.76 | 179.00 | -176.55 | 196.54 | 5.34 | 255.21 | ||||||
Interest & Other Items | 19.93 | 6.74 | 16.66 | 46.25 | 50.61 | 49.74 | ||||||
PBT | 113.83 | 172.26 | -193.21 | 150.29 | -45.27 | 205.47 | ||||||
Taxes & Other Items | 70.17 | 49.56 | 59.34 | 55.44 | -41.24 | -72.27 | ||||||
Net Income | 43.66 | 122.70 | -252.55 | 94.85 | -4.03 | 277.74 | ||||||
EPS | 3.05 | 16.41 | -33.77 | 6.63 | -0.28 | 19.41 | ||||||
DPS | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | ||||||
Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Investor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Akums Drugs and Pharmaceuticals Ltd | -2,499.95 | 13.98 | — |
Sun Pharmaceutical Industries Ltd | 44.98 | 6.42 | 0.75% |
Cipla Ltd | 29.13 | 4.48 | 0.87% |
Torrent Pharmaceuticals Ltd | 64.71 | 15.63 | 0.88% |
Price Comparison
Compare AKUMS with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
No institutional holdings trend are available
Shareholding Pattern
Feb 2024
Aug 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
No mutual funds holding trends are available
Top 5 Mutual Funds holding Akums Drugs and Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Franklin India Smaller Companies Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.4457% | Percentage of the fund’s portfolio invested in the stock 1.04% | Change in the portfolio weight of the stock over the last 3 months 0.93% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 63/103 (+24) |
SBI Healthcare Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7521% | Percentage of the fund’s portfolio invested in the stock 2.22% | Change in the portfolio weight of the stock over the last 3 months 0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 22/33 (-3) |
Franklin India Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6472% | Percentage of the fund’s portfolio invested in the stock 1.16% | Change in the portfolio weight of the stock over the last 3 months 1.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 57/74 (+5) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
AKUMS has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Under the agreement, Akums was granted exclusive rights to sell a selection of Caregen's products in India for the duration of the partnership. The company would also be responsible for the packaging, marketing, and selling of Caregen's bulk products under either Caregen's trademark, Akums' trademark, or Akums' clients' trademarks. Caregen is a global leader in peptide research and development and a global biotechnology company based in South Korea that has commercialized the unlimited expandability of its patented peptides as many innovative products. Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The pharma company consolidated net profit spiked 104.96% to Rs 65.20 crore despite of 12.54% declined in revenue from operations to Rs 1,033.1 crore in Q2 FY25 over Q2 FY245.Powered by Capital Market - Live
Net profit of Akums Drugs & Pharmaceuticals rose 105.00% to Rs 65.21 crore in the quarter ended September 2024 as against Rs 31.81 crore during the previous quarter ended September 2023. Sales declined 12.54% to Rs 1033.09 crore in the quarter ended September 2024 as against Rs 1181.25 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1033.091181.25 -13 OPM %11.7312.85 - PBDT122.75144.95 -15 PBT87.89114.53 -23 NP65.2131.81 105 Powered by Capital Market - Live
Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live
Akums Drugs & Pharmaceuticals has entered into a License & Distribution Agreement with Triple Hair Inc, a company duly incorporated under the laws of New Brunswick, Canada, having its registered office at 5085 Principale-Est Av, Dieppe, New Brunswick, Canada. As per the terms of the agreement, Company has been granted the exclusive rights to further develop and market the products recently innovated by Triple Hair Inc, in the Territory of India. The Company will undertake this development and commercialization after obtaining the necessary regulatory approvals or requisite licenses in India. The agreement grants the Company exclusive right to use Triple Hair's intellectual property rights (Patent) solely to carry out the studies and perform the services as stipulated in the agreement. Further, Company will manage the commercial strategy to promote and offer Triple Hair's patented products to its own marketing partners and clients within the Indian market exclusively. Powered by Capital Market - Live
Revenue from operations was at Rs 1,019 crore in the quarter ended 30 June 2024, up 5.06% as against with Rs 969.89 crore posted in corresponding quarter last year. Profit before tax stood at Rs 87.47 crore in Q1 FY25 as compared pre tax loss of Rs 158.79 crore reported in Q1 FY24. The firm reported quarterly EBITDA of Rs 130.70 crore in Q1 FY25, registering a growth of 21.01% year on year. EBITDA margin improved to 12.7% in Q1 FY25 as compared to 11% recorded in the corresponding quarter previous year. The company's revenue from CMDO business was at Rs 782 crore in Q1 FY25, up 5.60% as against with Rs 740.50 crore posted in Q1 FY24. This was driven by strong growth in sales volume of 13.9%. Branded and generic formulations segment revenue stood at Rs 167.40 crore during the quarter, marking a de-growth of 12.49% year on year basis. The API segment revenue jumped 82.46% to Rs 69.70 crore in Q1 FY25 as against with Rs 38.20 crore posted in the corresponding quarter previous year. As on 30 June 2024, debt to equity improved to 0.25 times with Net debt at Rs 212.80 crore. Commenting on the financial performance, Sanjeev Jain, MD, Akums Drugs & Pharmaceuticals, stated, 'Our Q1 results show our ongoing efforts to optimize our operations and capitalise on our strengths in the CDMO segment. We are committed to driving sustainable growth across all our business segments and delivering value to our stakeholders.' Meanwhile, the company's board announced the new Injectable facility housed in Akums Healthcare started commercial production on 22 August 2024, with a capacity of 362 million units annually. Akums already has a significant presence in injectable CDMO space and this new facility is expected to consolidate its leadership position in Indian CDMO market. Further, the board of directors, approved a plan to set up two production facilities in Jammu at an overall investment of Rs 265 crore. These will be multi-dosage facilities across pharmaceutical and nutraceutical products. Speaking on the company's plans, Sandeep Jain, MD, Akums Drugs & Pharmaceuticals, said, 'The launch of our injectable facility and the Jammu expansion are key steps in our strategy to enhance our production capabilities. These developments, coupled with our ongoing efforts in R&D and innovation, are aligned with our endeavour to respond effectively to the evolving demands of our clients and the healthcare industry.' Lastly, the company's board appointment Amrut Medhekar as a Chief Executive Officer, CDMO business with effect from 24 August, 2024. Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. The script slipped 2.97% to currently trade at Rs 913.05 on the BSE.Powered by Capital Market - Live
Net profit of Akums Drugs & Pharmaceuticals reported to Rs 60.17 crore in the quarter ended June 2024 as against net loss of Rs 188.23 crore during the previous quarter ended June 2023. Sales rose 5.07% to Rs 1019.11 crore in the quarter ended June 2024 as against Rs 969.89 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1019.11969.89 5 OPM %12.56-12.92 - PBDT121.54-129.33 LP PBT87.48-159.04 LP NP60.17-188.23 LP Powered by Capital Market - Live
Akums Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 24 August 2024.Powered by Capital Market - Live
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant